{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458283716
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = o
| target = [[CD11a]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 159445-64-4
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Odulimomab''' is an investigational drug for the prevention of [[transplant rejection]]<ref name="Martin">{{cite journal|pmid=10715487|year=2000|last1=Martin|first1=X|last2=Da Silva|last3=Virieux|last4=Hadj Aissa|last5=Buffet|last6=Tiollier|last7=Dubernard|title=Protective effect of an anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation|volume=32|issue=2|pages=481|journal=Transplantation proceedings|doi=10.1016/S0041-1345(00)00849-6|first2=M|first3=SR|first4=A|first5=R|first6=J|first7=JM}}</ref><ref>{{cite journal|pmid=10615777|year=1999|last1=Crétolle-Vastel|first1=C|last2=Camby|last3=Cerf-Bensussan|last4=Cavazzana-Calvo|last5=Fischer|last6=Révillon|last7=Sarnacki|title=Role of calcineurin-dependent drugs on the immunosuppressive effect induced by the anti-LFA-1 antibody in a fetal intestinal transplantation model in mice|volume=124|issue=5|pages=503–10|journal=Chirurgie; memoires de l'Academie de chirurgie|first2=C|first3=N|first4=M|first5=A|first6=Y|first7=S}}</ref> and for the treatment of various [[immunological]] diseases.<ref>{{cite journal|pmid=10527686|year=1999|last1=Whitcup|first1=SM|last2=Chan|last3=Kozhich|last4=Magone|title=Blocking ICAM-1 (CD54) and LFA-1 (CD11a) inhibits experimental allergic conjunctivitis|volume=93|issue=2|pages=107–13|doi=10.1006/clim.1999.4775|journal=Clinical immunology (Orlando, Fla.)|first2=CC|first3=AT|first4=MT}}</ref><ref>{{cite journal|pmid=12134096|year=2002|last1=Corbascio|first1=M|last2=Mahanty|last3=Osterholm|last4=Qi|last5=Pearson|last6=Larsen|last7=Freise|last8=Ekberg|title=Anti-lymphocyte function-associated antigen-1 monoclonal antibody inhibits CD40 ligand-independent immune responses and prevents chronic vasculopathy in CD40 ligand-deficient mice|volume=74|issue=1|pages=35–41|journal=Transplantation|doi=10.1097/00007890-200207150-00007|first2=H|first3=C|first4=Z|first5=TC|first6=CP|first7=CE|first8=H}}</ref>

It is a [[mouse]] [[monoclonal antibody]] directed against the [[CD11a|alpha chain]] of the protein [[lymphocyte function-associated antigen 1]] which is involved in immune reactions.<ref name="Martin" />

==References==
{{reflist}}

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}